FDA Clears Diagnostic Reader for Coronary Artery Disease
September 26, 2007 - Rcadia Medical Imaging Ltd., developer of novel computer-aided diagnostic software, has received a second FDA clearance to market its COR Analyzer family of products, which assists in triaging patients for coronary artery disease (CAD).
The new approval includes segmentation of the coronary tree with no human intervention and automatic detection of pathologies in the main coronary arteries. Rcadia's COR Analyzer reportedly identifies coronary artery disease and is designed to help exclude patients without coronary arterial disease with a high negative predictive value (NPV).
Coronary CTA studies are sent from the CT scanner to the COR Analyzer, which uses proprietary image processing algorithms to analyze Coronary CTA studies to characterize patients and alert the reader which patients are most likely to have coronary arterial disease.
For more information: www.rcadia.com
More like this
- FDA Clears CAD Solution for CTA
- 20/20 Healthcare to Distribute Analyzer for Coronary CTAs
- Breakthrough CT Diagnostic Software Demonstrated 100 Percent-Accurate CAD Identification
- 100 Percent Accuracy with Newly Cleared Cardiac CT Software
- ACC: 100 Percent Accuracy with Rcadia’s Newly Cleared Cardiac CT Software